CMPS, US20451W1018

COMPASS Pathways stock gets new employee grants on Nasdaq

Published on 10/04/2026 at 23:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

COMPASS Pathways stock was last at USD 11.90 on October 2, 2026, while analysts set a USD 23.36 consensus target. New awards support planned growth toward a 2027 launch.

CMPS, US20451W1018, Illustration mit AI erstellt.

COMPASS Pathways stock was last at USD 11.90 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 0.42 percent from USD 11.95. The latest company event was a new employee equity program announced on October 2, 2026, as the biotechnology group prepares for its COMP360 regulatory and commercial plans.

Employee grants set the tone

According to Yahoo Finance on October 2, 2026, COMPASS granted options for 121,800 shares and restricted share units covering 58,000 shares to one senior leader.

The same announcement covered 97,100 options and awards for 46,200 shares for 10 newly hired non-executive employees. The senior leader options carry an exercise price of USD 12.44, while the awards for the new employees use USD 11.95, matching the American Depositary Share closing price on October 1, 2026.

COMP360 data support 2027 plans

Clinical evidence remains the central value driver. In its September 9, 2026 release, Compass Pathways reported an average 13-point MADRS reduction from baseline at Week 52 after an additional 25 mg COMP360 dose.

The release also reported 40%-45% response rates during the first six weeks after Part C treatment. The company said the rolling NDA review was underway, with final submission targeted for Q4 2026 and commercial launch targeted for the first half of 2027, subject to FDA approval.

Losses contrast with analyst optimism

The latest quarterly comparison is less favorable. MarketBeat reported that Q2 2026 GAAP EPS was a loss of USD 1.88, versus a consensus loss of USD 0.39, a shortfall of USD 1.49.

MarketBeat also reported a Moderate Buy consensus from 17 brokerages, including 14 Buy ratings, one Strong Buy, one Hold and one Sell. The average 12-month price target was USD 23.36, which lies 96.30 percent above the October 2, 2026 price of USD 11.90.

Cash value and trial risk matter

COMPASS reported USD 433.295 million in cash and cash equivalents for Q2 2026 in standardized financial data, while operating cash flow was negative USD 40.306 million for the quarter. These figures frame the company's transition from clinical development toward a potential commercial organization.

The clinical opportunity is paired with regulatory and funding risk. The company describes COMP360 as an investigational treatment, so the 2027 launch plan depends on FDA approval and successful completion of the regulatory process.

CMPS stock stays below its yearly high

CMPS was last at USD 11.90 on Nasdaq on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 4.88 to USD 15.87, and its market capitalization was USD 1.6 billion as of that date.